What Farmaceutici Damor does

Farmaceutici Damor S.p.A. is a privately held Italian pharmaceutical company founded in 1943 and headquartered in Naples, with a secondary office in Monza. The company develops, manufactures, and distributes bio-pharmaceutical products built around a proprietary active pharmaceutical ingredient, the Estratto Acquoso di Triticum Vulgare (aqueous wheat extract), and the related "Stimoline" compound family it has researched since 1946 in line with Prof. Vladimir Filatov's theories. Its product portfolio spans four categories: pharmaceutical specialties, medical devices (centered on the Fitostimoline line of gauzes, creams, hydrogels, sprays, and proctogel, plus the Clarema Fitogel), food supplements, and cosmetics. Manufacturing is conducted in-house at the GMP-certified Naples facility, which holds ISO 9001, ISO 13485, ISO 14001, and ISO 45001 certifications as well as PLANT BASED conformity.

The company's go-to-market is a direct distribution model through Italian pharmacies and healthcare providers, with no disclosed international presence beyond Italy. Akademy Pharma, an in-house R&D initiative, formalizes collaboration with university experts for both technical and scientific development of new products. In 2019, Farmaceutici Damor entered an EU-funded productive investment partnership with Invitalia and the Italian Ministry of Economic Development to requalify part of its Naples industrial facility and acquire equipment to increase manufacturing volumes, signaling capacity-led growth rather than aggressive market expansion. Pricing is not publicly disclosed and no revenue figures are available; the company operates as a focused, niche Italian pharma with strong regulated-market credentials but limited geographic diversification.

Name

Farmaceutici Damor

Website

https://damorpharma.it

Company type

Private

Founded year

1943

Operating status

Operating

Headcount range

101–250 employees

Short description

Farmaceutici Damor is a privately held Italian pharmaceutical company founded in 1943, manufacturing and distributing bio-pharmaceutical products based on its proprietary Triticum Vulgare extract API across medicines, medical devices, food supplements, and cosmetics through Italian pharmacies.

Ownership category

akta.pro rank

Headquarters

HQ city

Naples

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels2 records

Core offering

Farmaceutici Damor manufactures bio-pharmaceutical products based on its proprietary Estratto Acquoso di Triticum Vulgare (Stimoline compounds) discovered in 1946. The company produces pharmaceutical specialties, medical devices (wound care and dermatological products such as Fitostimoline and Clarema lines), food supplements, and cosmetics, integrating the full production cycle from API to finished product.

Product overview

Farmaceutici Damor is an Italian pharmaceutical company with a global vision that develops and manufactures a portfolio of bio-pharmaceutical products. The company's core focus is on natural bio-pharmaceutical innovation, particularly centered around the Triticum Vulgare extract (inspired by Prof. Vladimir Filatov's 'Stimoline' theories). The product portfolio spans four main categories: (1) Specialità Medicinali - pharmaceutical specialties including their API (Estratto Acquoso di Triticum Vulgare); (2) Dispositivi Medici - medical devices including the Fitostimoline line (gauze, cream, hydrogel, spray, proctogel) and Clarema Fitogel for dermatological use; (3) Integratori Alimentari - food supplements; and (4) Cosmetici - cosmetic products. The company operates through AKADEMY PHARMA, which collaborates with university experts for product development.

Differentiator

Problem solved

Functional benefit

Brands

• Akademy Pharma: A research and development initiative that develops products with support from the best university experts participating in both technical and scientific development phases.
• Fitostimoline
• Clarema

Products and services

• Fitostimoline Plus Spray A spray formulation medical device for wound care and dermatological use, part of the Fitostimoline product line based on Triticum Vulgare aqueous extract.
• Clarema Fitogel A hydrophilic gel medical device in an aluminum tube for dermatological and skin care applications.
• Specialità Medicinali Prescription and over-the-counter pharmaceutical specialties produced by Farmaceutici Damor, including products based on their core API Estratto Acquoso di Triticum Vulgare.
• Dispositivi Medici Medical devices including wound care products, dermatological gels, and sprays under brands like Fitostimoline (gauze, cream, hydrogel, spray, proctogel) and Clarema.
• Integratori Alimentari Food supplements and nutritional products manufactured by Farmaceutici Damor.
• Cosmetici Cosmetic products formulated and manufactured by Farmaceutici Damor.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Direct peers

• Fidia Farmaceutici: Italian specialty pharmaceutical company of comparable mid-market size with a similar mix of prescription pharmaceuticals, medical devices, and healthcare products. Closely comparable business model and channel structure to Farmaceutici Damor.
• Dompé Farmaceutici: Italian biopharmaceutical company with branded specialty pharma, OTC, and medical device offerings. Comparable in being an Italy-headquartered, privately controlled specialty pharma with integrated manufacturing.
• IBSA Farmaceutici: Swiss-Italian privately held specialty pharma with a portfolio spanning prescription drugs, medical devices, and consumer health. Comparable mid-size specialty structure with adjacent therapeutic and dermocosmetic focus.
• ConvaTec: Global medical device specialist in advanced wound care, ostomy, and continence care. Direct competitor to Damor's Fitostimoline wound care franchise in advanced wound dressings and skin integrity products.
• Mölnlycke Health Care: Swedish-headquartered global leader in wound care and surgical solutions. Directly comparable as a wound care and dermatology medical device specialist competing with Fitostimoline and Clarema in the same indications.
• Coloplast: Danish global medical device company with a strong wound and skin care franchise alongside ostomy and continence. Comparable in wound/skin care medical device positioning and dermatology-adjacent product strategy.
• Urgo Medical: French-headquartered wound care medical device specialist (part of Urgo Group). Directly comparable in advanced wound dressings, dermatology, and skin integrity products targeting overlapping customer segments.

Broad incumbents

• Angelini Pharma: Privately held Italian pharmaceutical group with a broader prescription and consumer health portfolio. Comparable Italian specialty pharma heritage and channel strategy but operating at significantly greater scale.
• Chiesi Farmaceutici: Large privately held Italian pharmaceutical group with specialty and rare disease franchises. Comparable Italian family-controlled pharma heritage but with a substantially larger and more diversified footprint.
• Polpharma: Polish-headquartered European specialty pharmaceutical manufacturer with OTC and prescription generics. Comparable European mid-large specialty pharma with a manufacturing-led, multi-category portfolio strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/farmaceutici-damor

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Farmaceutici Damor